Celgene (CELG) says 52-week results demonstrate apremilast produces "meaningful improvements" in...

|About: Celgene Corporation (CELG)|By:, SA News Editor

Celgene (CELG) says 52-week results demonstrate apremilast produces "meaningful improvements" in ACR scores for patients with psoriatic arthritis. The company will present the data at the European Congress of Rheumatology later today. SA contributor Todd Campbell says the drug "offers upside" for CELG shares and notes that "analysts expect apremilast may generate sales of $300-500M/year." Shares +1.5% premarket.